Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.




On November 17, 2021, Pfizer Inc. ("Pfizer" or the "Company") announced that
Frank D'Amelio will retire from his position as Chief Financial Officer and
Executive Vice President of Global Supply after nearly 15 years of distinguished
service with the company. Pfizer has initiated an external search for a new
Chief Financial Officer. Mr. D'Amelio will continue to serve as CFO until his
successor is in place. Mr. D'Amelio made the following statement in connection
with this announcement, "It's been a privilege and a pleasure to work with
Albert Bourla and my Pfizer colleagues. I remain a tremendous supporter of the
Company, its leadership and direction."

Mr. D'Amelio led both the Finance and Pfizer Global Supply ("PGS") functions,
having been asked by the Company to take on PGS in 2019. Having successfully
completed the initial manufacturing and supply of the Pfizer-BioNTech COVID-19
vaccine, COMIRNATY, under Mr. D'Amelio's leadership, the Company had determined
that PGS will begin reporting directly to the CEO. The current leader of this
function, Michael McDermott, will also become a member of the Executive
Leadership Team. This organizational change is driven by the company's desire to
ensure continued high level focus and attention on all aspects of supply,
manufacturing and quality.

Following the appointment of a new chief financial officer, Mr. D'Amelio will
stay on as an employee advisor for a period of up to 12 months in order to
ensure a smooth transition of his CFO and PGS responsibilities. Due to the
impact of separating the leadership of the finance and supply functions, the
Compensation Committee of the Board of Directors determined that the application
of the Pfizer Executive Severance Plan was warranted and Mr. D'Amelio will be
eligible to receive severance pursuant to the terms of that plan following the
end of his employment.

A copy of the press release announcing Mr. D'Amelio's retirement is attached as
Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by
reference.


Item 9.01.   Financial Statements and Exhibits.



(d)  Exhibits.

Exhibit No.          Exhibit Description
  99.1               Press Release of Pfizer Inc. dated November 17, 2021
                     Cover Page Interactive Data File--the cover page XBRL tags are embedded within the
104                  Inline XBRL document.







--------------------------------------------------------------------------------



                                 Exhibit Index
Exhibit No.           Exhibit Description
  99.1                Press Release of Pfizer Inc. dated November 17, 2021
                      Cover Page Interactive Data File--the cover page XBRL tags are embedded
104                   within the Inline XBRL document.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses